NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
Table 16Selectivity Data Versus Aurora B for Selected Quinoxalinone Analogs
| Entry No. | CID SID Broad ID | * |
 | Potency (μM) Mean ± S.E.M. (n=replicates) | Fold Selectivity | ||||
|---|---|---|---|---|---|---|---|---|---|
| STK33 | Aurora B | ||||||||
| R1 | R2 | n | IC50 | n | IC50 | ||||
| 1 | 3163413 125299372 BRD-K86755954 | S |
 | 4-Cl | 3 | 0.16 ± 0.03 | 1 | > 10 | > 60 |
| 2 | 5337742 125299375 BRD-K20154023 | S |
| 4-F | 3 | 0.41 ± 0.03 | 1 | > 10 | > 20 |
| 3 | 53377438 125299373 BRD-K11118992 | S |
| 4-OMe | 3 | 0.25 ± 0.03 | 1 | > 10 | > 40 |
| 4 | 53377429 125299374 BRD-K79661811 | S |
| 4-OCF3 | 3 | 0.11 ± 0.01 | 1 | > 10 | > 90 |
| 5 | 53377448 125299367 BRD-K48188942 | S |
| 4-iPr | 3 | 0.014 ± 0.006 | 1 | 7.8 | 550 |
| 6 | 53377411 125299378 BRD-K09265391 | S |
| 5-Cl | 3 | 0.27 ± 0.05 | 1 | > 10 | > 35 |
| 7 | 53377419 125299379 BRD-K66645150 | S |
| 5-F | 3 | 0.078 ± 0.018 | 1 | > 10 | > 130 |
| 8 | 3162043 99351038, 125081988 BRD-K91863345 | S |
| H | 3 | 0.28 ± 0.03 | 1 | > 10 | > 35 |
| 9 | 53347979 125081982 BRD-K05922103 | S |
 | H | 3 | 0.076 ± 0.006 | 1 | > 10 | > 130 |
| 10 | 53347999 125081977 BRD-K51962689 | S |
 | H | 3 | 0.58 ± 0.02 | 1 | > 10 | > 15 |
| 11 | 7186158 125081981 BRD-K30634593 | S |
 | H | 3 | 0.15 ± 0.02 | 1 | > 10 | > 65 |
| 12 | 5019834 125081983 BRD-K82654216 | S |
 | H | 3 | 0.98 ± 0.18 | 1 | > 10 | > 10 |
- *
P=purchased; S=synthesized
- PubChem SubstanceRelated PubChem Substances
- A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells.[ACS Med Chem Lett. 2012]A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells.Weïwer M, Spoonamore J, Wei J, Guichard B, Ross NT, Masson K, Silkworth W, Dandapani S, Palmer M, Scherer CA, et al. ACS Med Chem Lett. 2012 Dec 13; 3(12):1034-1038. Epub 2012 Oct 22.
- STK33 kinase activity is nonessential in KRAS-dependent cancer cells.[Cancer Res. 2011]STK33 kinase activity is nonessential in KRAS-dependent cancer cells.Babij C, Zhang Y, Kurzeja RJ, Munzli A, Shehabeldin A, Fernando M, Quon K, Kassner PD, Ruefli-Brasse AA, Watson VJ, et al. Cancer Res. 2011 Sep 1; 71(17):5818-26. Epub 2011 Jul 8.
- Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.[J Exp Med. 2012]Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33.Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, Gößele U, Koch B, Faber K, Genze F, Schrader M, et al. J Exp Med. 2012 Apr 9; 209(4):697-711. Epub 2012 Mar 26.
- Review KRAS mutations in lung cancer.[Clin Lung Cancer. 2013]Review KRAS mutations in lung cancer.Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA, Rosell R. Clin Lung Cancer. 2013 May; 14(3):205-14. Epub 2012 Nov 1.
- Review Gene methylation in gastric cancer.[Clin Chim Acta. 2013]Review Gene methylation in gastric cancer.Qu Y, Dang S, Hou P. Clin Chim Acta. 2013 Sep 23; 424:53-65. Epub 2013 May 10.
- Table 16, Selectivity Data Versus Aurora B for Selected Quinoxalinone Analogs - ...Table 16, Selectivity Data Versus Aurora B for Selected Quinoxalinone Analogs - Probe Reports from the NIH Molecular Libraries Program
Your browsing activity is empty.
Activity recording is turned off.
See more...